Abstract
The purpose of this article was to present a case of successful long term treatment with azacitidine in patient with Chronic Myelomonocytic Leukemia (CMML) and discussing possible contributing factors for its long term efficacy. Data from our case were compared with similar data available in the literature. Effective treatment with azacitidine resulted in overall survival of 11 years 5 months and we showed that applying multiple cycles of treatment is feasible. Our patient received 71 cycles of treatment with total duration of 7 years and 3 months. Our report about a patient with CMML and a good clinical course revealed, that long term treatment with azacitidine is feasible in some patients. Initially low bone marrow blast count, a relatively small malignant CMML clone, reduction of spleen size and fast platelet response seemed to be factors determining long term response to treatment in our patient. More data on CMML treatment by Hypomethylating Agents and their analysis are needed in order to make firm conclusions.
Highlights
Ia Our report about a patient with Chronic ly Myelomonocytic Leukemia (CMML) and c a good clinical course revealed, that long r term treatment with azacitidine is feasible e in some patients
Effective treatment with e azacitidine resulted in overall survival of 11 s years 5 months and we showed that applyu ing multiple cycles of treatment is feasible. l Our patient received 71 cycles of treatment with total duration of 7 years and 3 months
More data on CMML c treatment by Hypomethylating Agents and - their analysis are needed in order to make Non firm conclusions
Summary
Ia Our report about a patient with CMML and c a good clinical course revealed, that long r term treatment with azacitidine is feasible e in some patients. Low bone marrow blast count, a relatively small malignant m CMML clone, reduction of spleen size and fast platelet response seemed to be factors m determining long term response to treato ment in our patient.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have